To explore the pathophysiological significance of the obese (ob) gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats, we examined the synthesis and secretion of leptin and its satiety effect in VMH-lesioned rats compared with those in sham-operated rats. Northern blot analysis revealed that ob gene expression is markedly augmented in the mesenteric and sc white adipose tissue, but remained unchanged in the epididymal white adipose tissue during the development of obesity in VMH-lesioned rats. Plasma leptin levels were relatively constant in sham-operated rats, but were elevated during the development of obesity in VMH-lesioned rats. In shamoperated rats, a single iv (1.0 mg/rat) or intracerebroventricular (2.0 g/rat) injection of recombinant human leptin reduced food intake and body weight gain in sham-operated rats. By contrast, no significant effect on food intake or body weight gain was observed in VMHlesioned rats. The present study provides evidence that VMH-lesioned rats overproduce leptin and increase its release but cannot respond to it and suggests that the loss of its satiety effect contributes to the development of obesity and the obesity-related phenotypes in VMH-lesioned rats. (Endocrinology 138: 947-954, 1997) P ARABIOSIS (or cross-circulation) experiments have suggested that mice homozygous for the obese (ob) mutation known as ob/ob mice develop marked obesity and diabetes because of the failure to produce a circulating satiety factor, whereas diabetes (db) mice or db/db mice, which are phenotypically indistinguishable from ob/ob mice on the same strain background, are unable to respond to it (1). Friedman and colleagues (2) reported positional cloning of the mouse ob gene and its human homolog. The ob gene encodes a 166-/167-amino acid polypeptide (called leptin) that is secreted specifically from the adipose tissue (2-5). Genetic evidence has indicated that a nonsense mutation occurs in the ob gene from ob/ob mice (2). We and others previously showed that ob gene expression and leptin secretion are augmented in rodent and human obesity in proportion to disease severity (2, 3, 5-13). It has been reported that recombinant leptin reduces food intake and body weight gain in mice and corrects the obesity-related phenotypes in ob/ob mice, but not in db/db mice (14 -18). Collectively, these findings indicate that leptin represents a fat cell-derived blood-borne satiety factor in which ob/ob mice are deficient and to which db/db mice are resistant.
during the development of obesity in VMH-lesioned rats. In shamoperated rats, a single iv (1.0 mg/rat) or intracerebroventricular (2.0 g/rat) injection of recombinant human leptin reduced food intake and body weight gain in sham-operated rats. By contrast, no significant effect on food intake or body weight gain was observed in VMHlesioned rats. The present study provides evidence that VMH-lesioned rats overproduce leptin and increase its release but cannot respond to it and suggests that the loss of its satiety effect contributes to the development of obesity and the obesity-related phenotypes in VMH-lesioned rats. (Endocrinology 138: 947-954, 1997) P ARABIOSIS (or cross-circulation) experiments have suggested that mice homozygous for the obese (ob) mutation known as ob/ob mice develop marked obesity and diabetes because of the failure to produce a circulating satiety factor, whereas diabetes (db) mice or db/db mice, which are phenotypically indistinguishable from ob/ob mice on the same strain background, are unable to respond to it (1) . Friedman and colleagues (2) reported positional cloning of the mouse ob gene and its human homolog. The ob gene encodes a 166-/167-amino acid polypeptide (called leptin) that is secreted specifically from the adipose tissue (2) (3) (4) (5) . Genetic evidence has indicated that a nonsense mutation occurs in the ob gene from ob/ob mice (2). We and others previously showed that ob gene expression and leptin secretion are augmented in rodent and human obesity in proportion to disease severity (2, 3, (5) (6) (7) (8) (9) (10) (11) (12) (13) . It has been reported that recombinant leptin reduces food intake and body weight gain in mice and corrects the obesity-related phenotypes in ob/ob mice, but not in db/db mice (14 -18) . Collectively, these findings indicate that leptin represents a fat cell-derived blood-borne satiety factor in which ob/ob mice are deficient and to which db/db mice are resistant.
The hypothalamus seems to be the main control center of satiety and energy expenditure (19) . It has been demonstrated that recombinant leptin decreases the hypothalamic production of neuropeptide Y, a potent stimulator of food intake (17, 20) . Peripheral administration of leptin induces expression of the immediate early gene c-fos, a marker of neuronal activation, in the hypothalamus (21) . A leptin receptor has been isolated that is encoded by the db gene (22) . The receptor has several alternatively spliced isoforms, one of which is expressed at a high level (23) in the hypothalamus and is missing in db/db mice due to a point mutation leading to its aberrant transcript (24, 25) . These findings, taken together, suggest that leptin exerts its satiety effect via the hypothalamus.
Bilateral lesions of the ventromedial hypothalamus (VMH) result in the development of obesity (19) , and thus VMH-lesioned animals have been widely used to study the mechanisms of body weight regulation. Previous studies have revealed that bilateral VMH lesions in one of a parabiotic pair lead to an increase in food intake and obesity in the lesioned rats, but result in a decrease in food intake and body weight leading to death by starvation in the unlesioned animals (26, 27) . These findings strongly suggest that VMHlesioned rats overproduce a circulating satiety factor to which the unlesioned animals can respond but VMH-le-sioned rats cannot. However, the molecular basis for such a factor has been undefined. In the present study, to explore the pathophysiological significance of leptin in VMH-lesioned rats, we examined its synthesis and secretion in VMHlesioned rats compared with those in sham-operated controls. We also studied the effects of iv or intracerebroventricular (icv) injection of recombinant leptin on food intake and body weight in these animals.
Materials and Methods Animals
Eight-week-old Sprague-Dawley rats were used in the present study. Rats were maintained in Shionogi Research Laboratories (Shiga, Japan). The animals were housed in a temperature-, humidity-, and light-controlled room (12-h light/12-h dark cycle) and allowed free access to water and standard rat chow (CE-2, 352 Cal/100 g, Japan CLEA, Tokyo, Japan).
VMH lesions
Rats were anesthetized by ip injection of Nembutal (50 mg/kg; Abbott Laboratories, North Chicago, IL). Bilateral VMH lesions were made through stereotaxically positioned stainless steel electrodes (50 mA, 40 sec) using coordinates from the atlas of Paxinos and Watson (2.56 mm posterior to the bregma, Ϯ0.4 mm lateral, 9.5 mm from the dural surface) (28) . At the end of the experiments, areas of the hypothalamic lesions in all animals were determined histologically by hematoxylin and eosin staining. Only the animals that showed bilateral VMH lesions were included in the present study. Control animals received sham VMH lesions (no current passing through the electrode).
Tissue and plasma samplings
Rats were used before and 1, 5, 10, and 30 days after the VMH lesions. After rats were decapitated at 0900 h, blood was sampled, and the white adipose tissue (WAT) was removed immediately from the mesenteric, sc abdominal, and epididymal fat pads. Plasma glucose, triglyceride, and insulin levels were measured as previously described (3, 13) . Plasma leptin levels were determined using the RIA for rat leptin as described below. The adipose tissue was frozen in liquid nitrogen and stored at Ϫ70 C until use.
RNA extraction and Northern blot analysis
Total RNA extraction was carried out, and Northern blot analysis was performed with the 32 P-labeled rat ob complementary DNA (cDNA) probe as previously described (3) . A human ␤-actin genomic probe (Wako Pure Chemical, Osaka, Japan) was used to monitor the amount of total RNA in each sample. Rat ob messenger RNA (mRNA) levels were normalized to the ␤-actin mRNA levels in the adipose tissue to correct for differences in the amount of RNA applied. mRNA levels (arbitrary units) were expressed relative to those of mesenteric WAT from 8-weekold Sprague-Dawley rats before the VMH lesions (the ob mRNA level in 10 g total RNA from the mesenteric WAT in 8-week-old rats was defined as 1 U).
RIA for rat leptin
A full-length rat ob cDNA clone (3) was used as template in the PCR with primers (sense, 5Ј-GTGCCTATCCACAAAGTCCAGGAT-3Ј; antisense, 5Ј-GCATTCAGGGCTAAGGTCCAACTG-3Ј) selected to amplify sequences corresponding to amino acids 22-167 (3). The PCR product was subcloned into the pET-3c expression vector (Takara Shuzo Co., Shiga, Japan) (29) . Expression and purification of recombinant rat leptin-(22-167) were performed as previously described (13, 29) . Recombinant rat leptin was radioiodinated by the chloramine-T method. The specific activity of [ 125 I]rat leptin ranged from 62.5-72.5 Ci/g. An antiserum for rat leptin was raised in Japanese white rabbits immunized with recombinant rat leptin, which was used at a 1:5000 final dilution. RIA for rat leptin was performed following the method of RIA for human leptin (13) . Rat plasma leptin levels were determined using the RIA for rat leptin.
Preparation of recombinant human leptin
A full-length human ob cDNA clone (4) was used as template in PCR with primers (sense, 5Ј-TACGTACCCATCCAAAAAGTCCAA-3Ј; antisense, 5Ј-AGGCCT-CAGCACCCAGGGCTGAG-3Ј) selected to amplify sequences corresponding to amino acids 22-166 (4). The PCR product was subcloned into the NcoI site of the pTrc99A vector (Pharmacia LKB Biotechnology, Piscataway, NJ), and the resulting pTacOb was verified by sequencing. Escherichia coli DH5␣ was transformed with pTacOb, and the recombinant human leptin protein was expressed and purified essentially as previously described (30) . In brief, proteins were concentrated and suspended in a solution containing 50 mm Tris-HCl (pH 8.5), 100 mm NaCl, 1 mm dithiothreitol, and 8 m urea; dialyzed against graded concentrations of urea containing 50 mm Tris-HCl (pH 8.5) and 100 mm NaCl; and resuspended in 50 mm Tris-HCl (pH 8.5) and 100 mm NaCl. The protein solution was fractionated by gel filtration on a HiLoad Superdex 75pg 16/60 column (Pharmacia LKB Biotechnology), and fractions were analyzed by SDS-PAGE and staining for protein with Coomassie blue. Protein concentrations were determined by the Bradford method (31) .
iv and icv injections of recombinant leptin
One day after the VMH lesions, rats were injected with recombinant leptin or vehicle from the tail vein. For icv injection, a stainless steel cannula (od, 1.09 mm; Becton Dickinson, Sparks, MD) was implanted as previously described (32) in the skull of rats 5 days before the VMH lesions, using coordinates (6.5 mm anterior to the lambdoidal suture, Ϯ1.4 mm lateral to the midline, 4.5 mm from the dural surface) (28) . The icv cannula placement was confirmed in all animals by introducing Evans blue dye after the experiments. Only the animals that showed bilateral VMH lesions and correct icv cannula placement were included in the present study. The test solution was injected with a microsyringe into sham-operated and VMH-lesioned rats. Cumulative food intake was measured 1 day after the iv or icv injection. Body weight change was measured after the VMH lesions. In normal rats, a single iv or icv injection of recombinant leptin caused dose-related reductions in food intake and body weight (iv, 0.2-1.0 mg/0.5 ml saline⅐rat; icv, 0.25-2.0 g/10 l saline⅐rat) (Satoh, N., Y. Ogawa, G. Katsuura, and K. Nakao, unpublished data), which were comparable to those into mice reported previously (14 -18) . In the present study, therefore, leptin was injected at the maximal doses (iv, 1.0 mg/rat; icv, 2.0 g/rat).
Statistical analysis
All data were expressed as the mean Ϯ sem. The statistical significance of differences in mean values was assessed by Duncan's multiple range test after one-way ANOVA.
Results

Profiles of sham-operated and VMH-lesioned rats
Just after the VMH lesions, the food intake of rats with bilateral VMH lesions increased significantly compared with that of sham-operated rats, which was observed throughout the experiments (Fig. 1A) . VMH-lesioned rats gained weight more rapidly than sham controls during the first postoperative day, resulting in 125.7 Ϯ 4.8 and 260.5 Ϯ 17.4 g gains in sham-operated and VMH-lesioned rats, respectively, at the end of the experiments (Fig. 1B) . In VMH-lesioned rats, the plasma insulin level was elevated throughout the experiments (Fig. 1E) . Plasma glucose and triglyceride levels were increased in VMH-lesioned rats 1 day after the surgery; thereafter, these levels were roughly equivalent in shamoperated and VMH-lesioned rats (Fig. 1, C and D) .
Expression of the ob gene in sham-operated and VMHlesioned rats
Northern blot analysis revealed that the ob gene is expressed abundantly in the mesenteric, sc, and epididymal WAT in 8-week-old Sprague-Dawley rats (Fig. 2A) . The rank order of the ob mRNA level was epididymal WAT Ͼ sc WAT Ͼ mesenteric WAT (Fig. 2B) . In the present study, no significant changes in the ob mRNA level were noted in WAT examined in sham-operated rats throughout the experiments (Fig. 2B) .
Expression of the ob gene was not changed in the mesenteric and sc WAT in VMH-lesioned rats compared with that in sham-operated controls 1 day after the VMH lesions (Fig.  2) . Thereafter, ob gene expression was markedly augmented in mesenteric and sc WAT during the progression of obesity in VMH-lesioned rats. The ob mRNA levels in mesenteric WAT from VMH-lesioned rats were 8.9-and 7.5-fold higher than those from sham-operated rats 10 and 30 days after the VMH lesions, respectively (P Ͻ 0.01). Expression of the ob gene was also augmented in sc WAT in VMH-lesioned rats 10 and 30 days after the VMH lesions (4.7-and 4.0-fold, respectively, vs. sham-operated rats; P Ͻ 0.01). By contrast, ob gene expression remained unchanged in epididymal WAT in VMH-lesioned rats throughout the experiments (Fig. 2) .
RIA for rat leptin
In the standard curve of the RIA for rat leptin (Fig. 3) , the minimal detectable quantity was 0.1 ng/tube, and the 50% binding intercept was 1.3 ng/tube. Intra-and interassay coefficients of variation were 5.3% (n ϭ 10) and 5.9% (n ϭ 10), respectively.
Plasma leptin levels in sham-operated and VMH-lesioned rats
Plasma leptin levels were relatively constant in shamoperated rats throughout the experiments (3.5-5.2 ng/ml; Fig. 4 ). Plasma leptin levels were significantly elevated in VMH-lesioned rats compared with those in sham-operated controls 1 day after the VMH lesions (2.1-fold vs. shamoperated rats; P Ͻ 0.05). Plasma leptin levels continued to be elevated in VMH-lesioned rats 5, 10, and 30 days after the VMH lesions compared with those in sham-operated rats (3.3-, 3.9-, and 9.1-fold, respectively, vs. sham-operated rats; P Ͻ 0.01; Fig. 4) .
Preparation of recombinant human leptin
The human ob cDNA was bacterially expressed, and the protein solution was analyzed by gel filtration. Fractions corresponding to M r of 10 -20 kDa (fractions 37-41) and approximately 30 kDa (fraction 34) were evaluated by SDS-PAGE and Coomassie blue staining. Fractions 37-41 gave a single band with an apparent M r of 16 kDa under both reducing and nonreducing conditions (Fig. 5) , indicating that the monomeric recombinant human leptin (22-166) was obtained. Western blot analysis using an antiserum raised against the NH 2 -terminal portion, 22-36, of
FIG. 1. Profiles of sham-operated and VMH-lesioned rats. Time course of food intake (A), body weight (B), and plasma glucose (C), triglyceride (D), and insulin (E) levels in sham-operated and VMH-lesioned rats (n ϭ 5). Values of sham-operated and VMH-lesioned rats are indicated by
open and closed circles, respectively. *, P Ͻ 0.05; **, P Ͻ 0.01 (vs. sham-operated rats).
human leptin revealed that the M r of the purified monomeric protein is identical to that of the native protein in the adipose tissue from obese patients (Ogawa, Y., G. Katsuura, N. Satoh, and K. Nakao, unpublished data). Fraction 34, on the other hand, gave a single band of approximately 30 kDa in size under nonreducing conditions, whereas a band with a M r of 16 kDa was detected under reducing conditions (Fig. 5) , suggesting dimer formation during the purification process. The monomeric recombinant leptin protein was used for further analysis. 
Effects of iv injection of recombinant leptin in shamoperated and VMH-lesioned rats
In sham-operated animals that received iv injection of the monomeric recombinant leptin (1.0 mg/0.5 ml saline⅐rat), food intake and body weight gain were significantly reduced. In sham-operated rats, a single iv injection of leptin at a dose of 1.0 mg/rat yielded a 57% decrease in food intake relative to that in vehicle-treated groups (Fig. 6A ). By contrast, no significant changes in food intake were observed in VMH-lesioned rats that received iv injections of leptin. In sham-operated rats that received a 1.0-mg leptin treatment, body weight gain was reduced significantly in leptin-treated groups, but was increased in vehicle-treated groups (4.0 Ϯ 2.9 g loss and 8.7 Ϯ 1.6 g gain, respectively, vs. the pretreatment values; Fig. 6B ). In VMH-lesioned rats, however, no significant differences in body weight gain were noted between leptin-and vehicle-treated groups (31.2 Ϯ 6.7 and 30.2 Ϯ 4.7 g gains, respectively, vs. the pretreatment values; Fig. 6B ).
Effects of icv injection of recombinant leptin in shamoperated and VMH-lesioned rats
A single icv injection of leptin (2.0 g/10 l saline⅐rat) significantly reduced food intake and body weight gain in sham-operated rats. Injection of leptin at a dose of 2.0 g/rat reduced food intake in sham-operated rats (91% decrease vs. vehicle-treated groups), but did not affect food intake in VMH-lesioned rats (Fig. 7A) . Body weight gain was also significantly reduced in sham-operated rats after icv injection of leptin at the same dose (0.3 Ϯ 2.2 g gain in vehicletreated groups and 27.7 Ϯ 3.1 g loss in leptin-treated groups vs. the pretreatment values; Fig. 7B ). By contrast, icv injection of leptin did not affect body weight gain in VMH-lesioned rats (24.0 Ϯ 11.0 and 19.4 Ϯ 9.8 g gains in vehicle-and leptin-treated groups, respectively, vs. the pretreatment values).
Discussion
The present study demonstrated augmented synthesis and secretion of leptin and loss of its satiety effect in VMHlesioned rats. Parabiosis studies between normal and VMHlesioned rats suggested that VMH-lesioned rats overproduce a circulating satiety factor, to which the unlesioned rats can respond but VMH-lesioned rats cannot (26, 27) . These observations are consistent with the results of the parabiosis experiments using db/db mice or fatty (fa) rats (fa/fa rats) and normal animals (33, 34) . It has been demonstrated that db/db mice and fa/fa rats develop obesity and diabetes because of a failure to respond to leptin (15) (16) (17) due to a mutation in the receptor gene that is expressed in the hypothalamus (23, 24, (35) (36) (37) , although ob gene expression and leptin secretion are markedly augmented in these animals (3, 7, 8, 10) . Collectively, we postulate that leptin represents one of the putative circulating satiety factors that VMH-lesioned rats overproduce but to which they cannot respond. Loss of the satiety effect of leptin should contribute to the development of obesity and the obesity-related phenotypes in VMH-lesioned rats as it does in db/db mice and fa/fa rats.
In the present study, the VMH lesions resulted in signif- icant hyperinsulinemia (38) . It has been shown that insulin stimulates ob gene expression in the development of obesity (39) . Therefore, hyperinsulinemia may be involved in the augmentation of ob gene expression and leptin secretion in VMH-lesioned rats. In this regard, we recently observed that ob gene expression remains increased in genetically obese KKA y mice after 72 h of fasting, when their obese phenotype remained but hyperinsulinemia was normalized (9) . These observations suggest that augmented expression of the ob gene is due not only to hyperinsulinemia but also to the obese phenotype per se in VMH-lesioned rats. The relationship between hyperinsulinemia and responsiveness to leptin is not clear at present. However, it has been demonstrated that leptin can be effective in mice with diet-induced obesity (16) , which must be hyperinsulinemic. It is, therefore, unlikely that hyperinsulinemia results in loss of the satiety effect of leptin in VMH-lesioned rats. It is conceivable that loss of the satiety effect of leptin in VMH-lesioned rats is due to the VMH lesions themselves. Direct microinjections of recombinant leptin into various hypothalamic regions are ongoing in our laboratory to determine whether the VMH is indeed the direct site of action of leptin or is located upstream and/or downstream to it.
The VMH has been implicated in the integration of the autonomic nervous system. In VMH-lesioned animals, sympathetic activity decreases, whereas vagal activity increases 19) . Recent studies have shown that sympathetic stimulation decreases ob gene expression in adipose tissue (40) . Dysregulation of the autonomic nervous system might be responsible for the augmentation of ob gene expression in VMH-lesioned rats. It has been demonstrated that recombinant leptin increases the otherwise decreased metabolic rate, body temperature, and locomotor activity in ob/ob mice (14) . Furthermore, leptin causes an increase in noradrenaline turnover to brown adipose tissue (41) . Collectively, these findings suggest that leptin increases sympathetic outflow. It is, therefore, tempting to speculate that the VMH lesions lead to a defect in the coupling of leptin-mediated afferent signals to the efferent autonomic neural pathways, which might contribute to the phenotypic changes in VMH-lesioned rats.
The present study represents the first report of plasma leptin levels in rats determined by RIA. The plasma levels in rats are comparable to those determined by RIA in humans (12, 13) . Furthermore, plasma leptin levels were significantly elevated during the development of obesity in VMH-lesioned rats compared with those in sham-operated rats, which is consistent with previous reports, using immnoblotting method, that plasma leptin levels are increased in several models of rodent obesity (8, 10, 11) . In the present study, ob mRNA levels were not statistically increased in mesenteric, sc, and epididymal WAT 1 and 5 days after the VMH lesions in VMH-lesioned rats compared with shamoperated rats. Differences in the time course between ob mRNA and plasma leptin levels may be due to differences in sensitivity between Northern blot analysis and RIA. It has been reported that normal weight animals made parabiotic with db/db mice, fa/fa rats, or VMH-lesioned rats reduce their food intake and body weight, and die of starvation (26, 27, 33, 34) . The phenotypic changes in normal animals may be explained in part by an increase in circulating leptin supplied by the obese partners. Further studies are needed to determine the range of plasma leptin levels required to induce a satiety effect in normal animals.
We and others have demonstrated that ob gene expression is augmented in ob/ob and db/db mice and fa/fa rats, all of which have a defect in leptin or its receptor (2, 23, 24, (35) (36) (37) . Furthermore, during fasting or food restriction, ob gene expression is down-regulated in normal animals, but not in these genetically obese animals (42, 43) . These findings suggest that a normal action of leptin is required for proper regulation of ob gene expression. Indeed, treatment with recombinant leptin decreases adipose tissue expression of the ob gene in ob/ob mice (44) . We have, therefore, postulated that augmented expression of the ob gene is due at least partly to the defective interactions between leptin and its receptor in ob/ob and db/db mice and fa/fa rats (3). Similarly, the augmentation of ob gene expression in VMH-lesioned rats is attributable to loss of the satiety effect of leptin.
The present study demonstrates that ob gene expression is markedly up-regulated in mesenteric and sc WAT, but remains unchanged in epididymal WAT during the progression of obesity in VMH-lesioned rats. These findings indicate that adipose tissue expression of the ob gene is augmented in a region-specific manner in VMH-lesioned rats. Funahashi et al. (6) previously showed that after the VMH lesions in rats, ob gene expression is augmented more rapidly in mesenteric WAT than in sc WAT. In the present study, however, no such difference was noted between these two fat pads. It has been shown that gold thioglucose-induced VMH lesions in mice induce obesity with differences in cellularity and weight among different fat pads (45) . Differences in cellularity and weight among different fat pads might result in regional differences in ob gene expression in the WAT from VMHlesioned animals.
In conclusion, we have demonstrated augmented expression of the ob gene and loss of the satiety effect of leptin in VMH-lesioned rats. The present study provides evidence that leptin represents one of the blood-borne satiety factors to which VMH-lesioned rats cannot respond and suggests that loss of the satiety effect of leptin contributes to the development of obesity and the obesity-related phenotypes in VMH-lesioned rats.
